FBXW7 and colorectal carcinoma: Recent literature has reported FBXW7 loss confers resistance to oxaliplatin and cisplatin chemotherapeutic agents,30,31 while CRC cell lines harboring FBXW7 mutations or deletions are sensitive to Rapamycin treatment.32